JPMorgan raised the firm’s price target on Immunome (IMNM) to $39 from $35 and keeps an Overweight rating on the shares. The firm views the company’s Q4 report as a “non-event” with Immunome’s upcoming catalysts remaining unchanged.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
- Immunome reports FY25 EPS ($2.43), consensus ($2.21)
- Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
- Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
- Immunome: Differentiated Oncology Portfolio and ADC Platform Underpin Buy Rating and $40 Price Target